Journal of Ophthalmology

Advances in Retinal Therapeutics

Publishing date
17 Oct 2014
Submission deadline
30 May 2014

1Cullen Eye Institute, Baylor College of Medicine, Houston, TX 77030, USA

2Bascom Palmer Eye Institute, Miami, FL 33136, USA

3Department of Ophthalmology, Mayo Clinic, Rochester, MN 55905, USA

4Department of Ophthalmology, University of Crete Medical School, 71003 Heraklion, Greece

Advances in Retinal Therapeutics


Recent years have seen monumental advances in the treatment of a multitude of retinal diseases through the development of several new medications (anti-VEGF agents, dexamethasone implants, ocriplasmin injection, and new nonsteroidal anti-inflammatory agents), the use of existing medications for new indications, and through the evolution of vitreoretinal surgical instrumentation, adjuvants, and techniques.

We invite clinical investigators to contribute original research articles as well as review articles that discuss early results of new drugs for retinal disease, that expand or better define the use of existing drugs for the treatment of retinal disease, or that demonstrate or report on the use of novel or recently developed surgical techniques or instruments. Potential topics include, but are not limited to:

  • Treatment of central serous chorioretinopathy
  • Treatment of diabetic retinopathy (diabetic macular edema, proliferative diabetic retinopathy, and tractional retinal detachment)
  • Treatment of age-related macular degeneration
  • Treatment of retinal detachment and/or proliferative vitreoretinopathy
  • Treatment of endophthalmitis
  • Treatment of cystoid macular edema
  • Treatment of macular hole, vitreomacular traction, and epiretinal membrane
  • Treatment of retinal vascular disease and its complications
  • Treatment of retinopathy of prematurity
  • Treatment of macular dystrophy, including Stargardt disease
  • Treatment of retinitis pigmentosa

Before submission authors should carefully read over the journal’s Authors Guidelines, which are located at Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at according to the following timetable:

Journal of Ophthalmology
 Journal metrics
Acceptance rate36%
Submission to final decision73 days
Acceptance to publication31 days
Impact Factor1.447

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.